ZA200810741B - Methodes for the preparation of biologically active compounds in nanoparticulate form - Google Patents

Methodes for the preparation of biologically active compounds in nanoparticulate form

Info

Publication number
ZA200810741B
ZA200810741B ZA200810741A ZA200810741A ZA200810741B ZA 200810741 B ZA200810741 B ZA 200810741B ZA 200810741 A ZA200810741 A ZA 200810741A ZA 200810741 A ZA200810741 A ZA 200810741A ZA 200810741 B ZA200810741 B ZA 200810741B
Authority
ZA
South Africa
Prior art keywords
methodes
preparation
biologically active
active compounds
nanoparticulate form
Prior art date
Application number
ZA200810741A
Other languages
English (en)
Inventor
Felix Meiser
Raffaele Cammarano
Frank Caruso
Almar Postma
Original Assignee
Iceutica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006903527A external-priority patent/AU2006903527A0/en
Application filed by Iceutica Ltd filed Critical Iceutica Ltd
Publication of ZA200810741B publication Critical patent/ZA200810741B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
ZA200810741A 2006-06-30 2007-06-29 Methodes for the preparation of biologically active compounds in nanoparticulate form ZA200810741B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2006903527A AU2006903527A0 (en) 2006-06-30 Methods For The Preparation Of Pharmaceutically Active Compounds in Nanoparticulate Form

Publications (1)

Publication Number Publication Date
ZA200810741B true ZA200810741B (en) 2010-05-26

Family

ID=41284114

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200810741A ZA200810741B (en) 2006-06-30 2007-06-29 Methodes for the preparation of biologically active compounds in nanoparticulate form

Country Status (6)

Country Link
US (1) US8808751B2 (xx)
CN (3) CN101568330A (xx)
BR (1) BRPI0713053A2 (xx)
NZ (4) NZ573823A (xx)
TW (2) TWI564033B (xx)
ZA (1) ZA200810741B (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5508003B2 (ja) 2006-06-30 2014-05-28 アイスイティカ ピーティーワイ リミテッド ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法
BRPI1014276B8 (pt) * 2009-04-24 2021-05-25 Iceutica Pty Ltd produção de nanopartículas encapsuladas em escala comercial
KR101679522B1 (ko) * 2009-04-24 2016-11-24 아이슈티카 피티와이 리미티드 생물학적 활성 물질의 용해 프로파일 개선방법
BRPI1014275B8 (pt) 2009-04-24 2021-05-25 Iceutica Pty Ltd composição que compreende partículas de indometacina dispersas em pelo menos dois materiais de moagem parcialmente moídos
CN102438610A (zh) 2009-04-24 2012-05-02 伊休蒂卡有限公司 双氯芬酸的新剂型
EP2421509B1 (en) * 2009-04-24 2017-11-22 Iceutica Pty Ltd. Production of encapsulated nanoparticles at high volume fractions
FR2953217B1 (fr) * 2009-11-27 2012-10-05 Ifremer Procede de depolymerisation de polysaccharides par broyage mecanique
US8740114B2 (en) 2010-01-07 2014-06-03 Metronic Xomed, Inc. System and method of bone processing
US8465582B2 (en) * 2010-03-16 2013-06-18 Taipei Medical University Process for producing inorganic interconnected 3D open cell bone substitutes
WO2012158380A1 (en) 2011-05-16 2012-11-22 Drexel University Disaggregation of aggregated nanodiamond clusters
TWI580442B (zh) * 2011-10-19 2017-05-01 傑特大學 醫藥毫微懸浮物
PL2969227T3 (pl) * 2013-03-15 2019-12-31 Sun Pharma Global Fze Formulacja octanu abirateronu
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
KR101742152B1 (ko) * 2014-02-27 2017-06-01 바로돈에스에프주식회사 비특이성 면역증강제 조성물 및 그 제조방법, 그리고 그 용도
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
CN108697700B (zh) 2016-02-04 2021-08-17 辛多美制药有限公司 氘代多潘立酮组合物和用于治疗病症的方法
EP3606506A4 (en) * 2017-04-07 2021-01-06 MAA Laboratories, Inc. PROCESS FOR IMPROVING THE SOLUBILITY AND BIOAVAILABILITY OF THERAPEUTICS
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
CN107281163B (zh) * 2017-07-05 2020-08-14 郑州大学 羧基化合物在促进载药纳米粒微球口服吸收方面的应用
CN109646423A (zh) * 2018-12-03 2019-04-19 泓博元生命科技（深圳）有限公司 含nadh的生物高分子纳米球及其制备方法与应用
CN111481514B (zh) * 2019-01-25 2023-01-10 鲁南制药集团股份有限公司 一种治疗高血脂的片剂及其制备方法
CN113508114B (zh) * 2019-02-27 2024-03-26 四川科伦博泰生物医药股份有限公司 以氮杂环丁烷衍生物为活性成分的口服药物组合物、其制备方法及用途
CN110170489B (zh) * 2019-05-31 2021-06-01 国网河南省电力公司新野县供电公司 一种高压配电柜带电清洗装置和方法
CN111939151A (zh) * 2020-07-04 2020-11-17 浙江工业大学 一种复合型阿霉素白蛋白纳米粒及其制备方法和应用
CN114088624B (zh) * 2021-11-09 2022-08-26 北京中检葆泰生物技术有限公司 用于谷物颗粒表面规则度检测设备
CN114166871B (zh) * 2022-02-15 2022-04-26 西南石油大学 一种陆相页岩油储层脆性评价方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
DE19932157A1 (de) * 1999-07-13 2001-01-18 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln
JP4763957B2 (ja) * 2000-05-10 2011-08-31 オバン・エナジー・リミテッド メディアミリング
ATE424811T1 (de) * 2000-08-31 2009-03-15 Jagotec Ag Gemahlene partikel
DE60222160T2 (de) * 2001-10-12 2008-06-12 Elan Pharma International Ltd., Athlone Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
WO2003063838A1 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Dry granulated formulations of azithromycin
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2004058216A2 (en) * 2002-12-17 2004-07-15 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
US20090028948A1 (en) * 2004-12-31 2009-01-29 Iceutica Pty Ltd Nanoparticle composition and methods of synthesis thereof
EP1973523A2 (en) 2005-12-15 2008-10-01 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration

Also Published As

Publication number Publication date
CN102895194B (zh) 2015-09-09
BRPI0713053A2 (pt) 2012-07-17
TWI564033B (zh) 2017-01-01
CN104288103A (zh) 2015-01-21
US20100092563A1 (en) 2010-04-15
CN102895194A (zh) 2013-01-30
NZ573823A (en) 2012-05-25
CN104288103B (zh) 2019-10-15
NZ599069A (en) 2013-10-25
TW200808377A (en) 2008-02-16
US8808751B2 (en) 2014-08-19
CN101568330A (zh) 2009-10-28
TWI645862B (zh) 2019-01-01
TW201609190A (zh) 2016-03-16
NZ705763A (en) 2016-10-28
NZ614995A (en) 2015-03-27

Similar Documents

Publication Publication Date Title
ZA200810741B (en) Methodes for the preparation of biologically active compounds in nanoparticulate form
IL243534B (en) Methods for the preparation of biologically active compounds in the form of nanoparticles
IL251175A0 (en) Stabilized dosage of picoplatin
GB0522027D0 (en) Controlled preparation of nanoparticle materials
EP2130552A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-GRP78 ANTIBODY AS AN ACTIVE SUBSTANCE
ZA200809971B (en) Nanoparticulate posaconazole formulations
IL199006A0 (en) Nanoparticulate formulations and methods for the making and use thereof
EP2078731A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT
HK1127877A1 (en) Composition containing peptide as the active ingredient
IL193408A0 (en) Antibody formulation
IL192159A0 (en) Nanoclusters for delivery of the therapeutics
LT3984528T (lt) Farmacinė kompozicija, apimanti nilotinibą
EP2057987A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING AN ENCAPSULATED STATINE NANOPARTICLE
PL2086516T3 (pl) Przetwarzana w stanie stopionym postać użytkowa imatynibu
PT2043610E (pt) Secagem de partículas contendo fármacos
GB0614586D0 (en) Pharmaceutical Formulation
IL194366A0 (en) Solid dosage formulations
GB0513984D0 (en) Dosage form
GB0616794D0 (en) Solid dosage form
IL187855A0 (en) Processes for the preparation of docetaxel
ZA200710664B (en) Processes for the preparation of docetaxel
EP1963350A4 (en) BIOLOGICALLY ACTIVE COMPOUNDS
GB0517279D0 (en) Biologically active compounds
AU2006903527A0 (en) Methods For The Preparation Of Pharmaceutically Active Compounds in Nanoparticulate Form
GB0619768D0 (en) Pharmaceutical composition comprising antibodies